C Difficile

Microbiota modulation in disorders of gut-brain interaction - PubMed
Microbiota modulation in disorders of gut-brain interaction - PubMed
Disorders of gut-brain interaction (DGBI) are common chronic conditions characterized by persistent and recurring gastrointestinal symptoms triggered by several pathophysiological factors, including an altered gut microbiota. The most common DGBI are irritable bowel syndrome (IBS), functional consti …
·pubmed.ncbi.nlm.nih.gov·
Microbiota modulation in disorders of gut-brain interaction - PubMed
The Role of Gut Microbiota in Male Erectile Dysfunction of Rats - PubMed
The Role of Gut Microbiota in Male Erectile Dysfunction of Rats - PubMed
Intestinal microbiota disorders induced by HFD can damage the intestinal barrier of rats, change the serum metabolic profile, induce low-grade inflammation and apoptosis in the corpus cavernosum of the penis, and lead to ED.
·pubmed.ncbi.nlm.nih.gov·
The Role of Gut Microbiota in Male Erectile Dysfunction of Rats - PubMed
Multiplexed Gastrointestinal PCR panels for the Evaluation of Diarrhea in HCT Recipients - PubMed
Multiplexed Gastrointestinal PCR panels for the Evaluation of Diarrhea in HCT Recipients - PubMed
MGPP testing is most useful when administered at hospital admission or as an outpatient. Since MGPP is sensitive and does not distinguish between colonization and causes of diarrhea, caution is needed in interpretation of results, especially for toxin negative C. difficile and diarrheagenic gram-neg …
·pubmed.ncbi.nlm.nih.gov·
Multiplexed Gastrointestinal PCR panels for the Evaluation of Diarrhea in HCT Recipients - PubMed
Research Progress on the Correlation Between Hypertension and Gut Microbiota - PubMed
Research Progress on the Correlation Between Hypertension and Gut Microbiota - PubMed
Among cardiovascular diseases, hypertension is the most important risk factor for morbidity and mortality worldwide, and its pathogenesis is complex, involving genetic, dietary and environmental factors. The characteristics of the gut microbiota can vary in response to increased blood pressure (BP) …
·pubmed.ncbi.nlm.nih.gov·
Research Progress on the Correlation Between Hypertension and Gut Microbiota - PubMed
Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs - PubMed
Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs - PubMed
First-line antihypertensive drugs induced different modifications of gut integrity and gut dysbiosis in SHR, which result in no contribution of microbiota in the BP lowering effects of hydrochlorothiazide, whereas the vasculo-protective effect induced by amlodipine involves gut microbiota reshaping …
·pubmed.ncbi.nlm.nih.gov·
Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs - PubMed
Non-prime- and prime-side profiling of Pro-Pro endopeptidase specificity using synthetic combinatorial peptide libraries and mass spectrometry - PubMed
Non-prime- and prime-side profiling of Pro-Pro endopeptidase specificity using synthetic combinatorial peptide libraries and mass spectrometry - PubMed
A group of bacterial proteases, the Pro-Pro endopeptidases (PPEPs), possess the unique ability to hydrolyze proline-proline bonds in proteins. Since a protease's function is largely determined by its substrate specificity, methods that can extensively characterize substrate specificity are valuable …
·pubmed.ncbi.nlm.nih.gov·
Non-prime- and prime-side profiling of Pro-Pro endopeptidase specificity using synthetic combinatorial peptide libraries and mass spectrometry - PubMed
Gastrointestinal Conditions: Acute Infectious Gastroenteritis and Colitis - PubMed
Gastrointestinal Conditions: Acute Infectious Gastroenteritis and Colitis - PubMed
Gastroenteritis is inflammation of the stomach and intestines; colitis is inflammation of the colon. Viruses are the most common cause, followed by bacteria and parasites. Incidence of the various infections varies by age, sex, location, and vaccine availability; vaccination has reduced rotavirus in …
·pubmed.ncbi.nlm.nih.gov·
Gastrointestinal Conditions: Acute Infectious Gastroenteritis and Colitis - PubMed
Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis - PubMed
Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis - PubMed
Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic cell transplantation (alloHCT) associated with gut microbiota disruptions. However, whether therapeutic microbiota modulation prevents aGVHD is unknown. We conducted a randomized, placebo-controlled trial of …
·pubmed.ncbi.nlm.nih.gov·
Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis - PubMed
Progress on mechanisms of antibiotic resistance in Clostridioides difficile - PubMed
Progress on mechanisms of antibiotic resistance in Clostridioides difficile - PubMed
Clostridioides difficile (CD) is one of the most common pathogens causing health-care-associated infectious diarrhea and is listed by the U.S. Centers for Disease Control and Prevention as an urgent antibiotic resistance (AR) threat. Many resistance genes can be transferred between different CD stra …
·pubmed.ncbi.nlm.nih.gov·
Progress on mechanisms of antibiotic resistance in Clostridioides difficile - PubMed
Benefits of Accepting Infectious Diseases Pharmacist Recommendations: A 5-Year Outcome Study in a Multihospital System - PubMed
Benefits of Accepting Infectious Diseases Pharmacist Recommendations: A 5-Year Outcome Study in a Multihospital System - PubMed
Background: Infectious diseases (ID) pharmacists are pivotal members of antimicrobial stewardship teams. Prospective audit and feedback is a strong recommendation by The Infectious Diseases Society of America Guidelines for Antimicrobial Stewardship Programs (ASP). Utilizing customized ASP in …
·pubmed.ncbi.nlm.nih.gov·
Benefits of Accepting Infectious Diseases Pharmacist Recommendations: A 5-Year Outcome Study in a Multihospital System - PubMed
Protection against Clostridioides difficile disease by a naturally avirulent C. difficile strain - PubMed
Protection against Clostridioides difficile disease by a naturally avirulent C. difficile strain - PubMed
Clostridioides difficile infections (CDI) are prevalent in healthcare settings and are associated with high recurrence rates. Therapies to prevent CDI, including recent FDA-approved live biotherapeutic products, are costly and have not been used to prevent primary infections. While a nontoxig …
·pubmed.ncbi.nlm.nih.gov·
Protection against Clostridioides difficile disease by a naturally avirulent C. difficile strain - PubMed
Bringing gut microbiota into the spotlight of clinical research and medical practice - PubMed
Bringing gut microbiota into the spotlight of clinical research and medical practice - PubMed
Despite the increasing scientific interest and expanding role of gut microbiota (GM) in human health, it is rarely reported in case reports and deployed in clinical practice. Proteins and metabolites produced by microbiota contribute to immune system development, energy homeostasis and digestion. Ex …
·pubmed.ncbi.nlm.nih.gov·
Bringing gut microbiota into the spotlight of clinical research and medical practice - PubMed
Metagenome-assembled genomes (MAGs) suggest an acetate-driven protective role in gut microbiota disrupted by Clostridioides difficile - PubMed
Metagenome-assembled genomes (MAGs) suggest an acetate-driven protective role in gut microbiota disrupted by Clostridioides difficile - PubMed
Clostridioides difficile may have a negative impact on gut microbiota composition in terms of diversity and abundance, thereby triggering functional changes supported by the differential presence of genes involved in significant metabolic pathways, such as short-chain fatty acids (SCFA). This work h …
·pubmed.ncbi.nlm.nih.gov·
Metagenome-assembled genomes (MAGs) suggest an acetate-driven protective role in gut microbiota disrupted by Clostridioides difficile - PubMed
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - PubMed
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - PubMed
Clostridioides difficile infection (CDI) is one of the leading causes of healthcare- and antibiotic-associated diarrhea. While fecal microbiota transplantation (FMT) has emerged as a promising therapy for recurrent CDI, its exact mechanisms of action and long-term safety are not fully underst …
·pubmed.ncbi.nlm.nih.gov·
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - PubMed
Novel C. diff structures are required for infection, offer new therapeutic targets
Novel C. diff structures are required for infection, offer new therapeutic targets
Newly discovered iron storage “ferrosomes” inside the bacterium C. diff — the leading cause of hospital-acquired infections — are important for infection in an animal model and could offer new targets for antibacterial drugs. They also represent a rare demonstration of a membrane-bound structure inside a pathogenic bacterium, upsetting the biological dogma that bacteria do not contain organelles. 
·news.google.com·
Novel C. diff structures are required for infection, offer new therapeutic targets
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism - PubMed
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism - PubMed
Recurrent Clostridioides difficile infection (CDI) results in significant morbidity and mortality. We previously established that CDI in mice does not protect against reinfection and is associated with poor pathogen-specific B cell memory (Bmem), recapitulating our observations with human Bmem. Here …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism - PubMed
Gut microbiota mediates the protective effects of β-hydroxybutyrate against cisplatin-induced acute kidney injury - PubMed
Gut microbiota mediates the protective effects of β-hydroxybutyrate against cisplatin-induced acute kidney injury - PubMed
The gut microbiota has been reported to be perturbed by chemotherapeutic agents and to modulate side effects. However, the critical role of β-hydroxybutyrate (BHB) in the regulation of the gut microbiota and the pathogenesis of chemotherapeutic agents related nephrotoxicity remains unknown. We condu …
·pubmed.ncbi.nlm.nih.gov·
Gut microbiota mediates the protective effects of β-hydroxybutyrate against cisplatin-induced acute kidney injury - PubMed
Critically Evaluating the Role for Postoperative Antibiotics in Patients Undergoing Urethroplasty With Buccal Mucosa Graft: A Claims Database Analysis - PubMed
Critically Evaluating the Role for Postoperative Antibiotics in Patients Undergoing Urethroplasty With Buccal Mucosa Graft: A Claims Database Analysis - PubMed
In this large retrospective cohort study of patients undergoing urethroplasty with BMG, we observed no significant benefit from use of postoperative antibiotics on long-term revision rates or perioperative infectious complications.
·pubmed.ncbi.nlm.nih.gov·
Critically Evaluating the Role for Postoperative Antibiotics in Patients Undergoing Urethroplasty With Buccal Mucosa Graft: A Claims Database Analysis - PubMed
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Clostridium Difficile Infections...
·news.google.com·
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports